heart failure glp 1 Effects of Glucagon-Like Peptide Receptor Agonist Initiation in Patients With With Reduced Ejection Fraction and Implantable Cardiac Devices Emerging Heart Failure Therapies in

Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity

The agency notes that the peptide is highly susceptible to protein aggregation and the accumulation of peptide-related manufacturing impurities when formulated for injection, which can trigger massive, systemic immune system reactions in human patients

Major challenges in hydrogel-based delivery systems include difficulties with large-scale production, difficulties in precisely controlling gelation, the risk of immunogenicity, and the possibility of uneven drug distribution and retention within brain tissues

Follow your device's specific instructions regarding skin pinching and injection angle